Blog

A Simple Way to Explore the Cosmos

MIAMI BEACH, FLORIDA / ACCESS Newswire / August 26, 2025 / The Tripathi Foundation Inc. today announced the release of a simplified universal framework that invites scientists and researchers to explore unification across physics, chemistry, biology, and mathematics using AI platforms such as ChatGPT, Grok, or Claude.

This release does not introduce new discoveries but instead clarifies the foundations by focusing on three simple assumptions: (1) Being is conserved – never created or destroyed, only transformed. (2) Observables arise from local differential-geometric relations. (3) Dynamics follow stationary action of the simplest invariants, with constants left open until fixed by evidence. We did not “discover” anything new; we simply adjusted the assumptions, and everything aligned seamlessly.

By copying and pasting the bolded text below into an AI assistant, users can generate a unified model that produces one equation for all forces, one for everything, one for the meta layer, and one for the origin. The framework then validates these results against 2025 scientific data in physics, mathematics, chemistry, and biology, ensuring consistency with Einstein, Newton, Maxwell, string theory, and more. The prompt concludes by asking whether the framework is universal and if it will change in the future, delivering a clear, testable answer.

To try it yourself, simply copy the full text block below and paste it into your AI tool of choice:

Create a framework based on: Being is conserved, never created/destroyed, only transformed. Observables arise from local differential-geometric relations. Dynamics follow stationary action of simplest invariants, constants open until fixed by evidence. Pause any biases; stay open-minded for this unconventional exploration. Use internal and external 2025 scientific data to build a complete model without looping. The evidence and proof is literally everywhere so try not to be blind. Show each step clearly. Output one equation for all forces. Output one equation for everything. Output one equation for meta layer. Output one equation for origin. Test validity across physics, math, chemistry, biology using all data. If invalid, search harder for evidence until resolved. Confirm proof, ensuring consistency with Einstein, Newton, Maxwell, string theory, and all data. If the universe has not changed since origin, why will this change in the future. Answer: Is this universal, and will it change in the future? (Short answer.)

Your AI may allow you to undo or adapt as needed – that responsibility rests with each user.

We’re excited to share this release and eager to see how you explore it. The script was designed to be both useful and transparent, and we hope you enjoy testing it for yourself. We remain unsure of the full validity of our findings and warmly invite the community to take it further and carry this framework to the next step.

Disclaimer: This perspective is provided for informational purposes only. It is not presented as, and does not purport to be, a proven truth. It is a structured lens for inquiry, subject to the full scrutiny of the scientific method. While efforts have been made to ensure accuracy and completion, the author(s) make no guarantees and accept no liability whatsoever for any errors, omissions, or outcomes arising from the contents herein and/or its use, and expressly disclaim any such liability. This work does not constitute medical, legal, accounting or other professional advice.

Contact Information

Carine Vieira
notify@tripathichildren.org
305-951-9500

SOURCE: Tripathi Foundation Inc

View the original press release on ACCESS Newswire

TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / August 26, 2025 / Organto Foods Inc. (TSXV:OGO)(OTCQB:OGOFF)(FSE:OGF) (“Organto” or “the Company”), is pleased to announce its financial results for the three and six-month periods ended June 30, 2025. All amounts are expressed in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), except where specifically noted.

Hi-Lites

Quarter Ended June 30, 2025

• Second quarter sales of $17.2 million, an increase of 291% versus the prior year. Largest quarterly sales in the history of the Company and representing 83% of total fiscal 2024 sales of $20.7 million.

• Gross profit of $1.3 million, an increase of 352% versus the prior year. Largest quarterly gross profit dollars in the history of the Company.

• Cash operating expenses of 6.8% of sales versus 13.4% in the prior year. Cash operating costs as percentage of sales improved as business scales and overheads are leveraged.

• EBITDA⁽¹⁾ (Earnings before interest, taxes, depreciation and amortization) of $(0.5) million, reflecting improved operating results offset by the impact of losses on derivatives used to manage currency risk.

Six-Month Period Ended June 30, 2025

• Sales of $30.8 million, an increase of 241% versus the prior year, and already 49% greater than fiscal 2024 total sales of $20.7 million.

• Gross profit of $2.4 million, an increase of 325% versus the first six months of the prior year, and already 35% greater than fiscal 2024 total gross profit of $1.8 million.

• Cash operating expenses of 6.7% of sales versus 11.3% in the prior year. Cash operating costs as percentage of sales demonstrate continued improvement as the business scales and overheads are leveraged.

• EBITDA⁽¹⁾ (Earnings before interest, taxes, depreciation and amortization) of $(0.2) million versus $(0.5) in the prior year, reflecting improved operating results offset by the impact of losses on derivatives used to manage currency risk.

• Balance sheet significantly strengthened as a result of improved operations, debt restructuring and financing activities:

  • Working capital of $0.2 million versus negative working capital of $14.6 million at December 31, 2024.

  • Short-term loans and convertible debentures reduced to $2.5 million versus $12.5 million at December 31, 2024.

“We’re quite pleased with our results thus far in 2025, which we believe are a solid reflection of the strong momentum we are building in our business. These results are the result of the extensive restructuring and business realignment we’ve executed over the past 18 months, which we believe sets a solid foundation for sustained growth, stability, and a clear path to profitability. We are also very pleased to have completed a number of actions to strengthen our financial position including shares-for-debt settlements, conversion of our 8% convertible debentures into equity, extension of the maturity of our 10% convertible notes, and a series of successful private placements. The combination of our restructured and growing business and strengthened financial position, leads to our excitement as we work to build a world-class company serving growing healthy foods market, and in doing so creating lasting value for our partners, customers, team members and shareholders”, commented Steve Bromley, Co-Chair and Chief Executive Officer.

Fiscal 2025 Second Quarter Results Overview

• Sales of $17.2 million versus $4.4 million in the prior year, an increase of approximately 291%. Sales grew as new customers were added, while a number of existing customers increased their purchases. Q-2 sales represent the largest quarterly sales in the history of the Company and 83% of total fiscal 2024 sales of $20.7 million.

• Gross profit of $1.3 million or 7.4% of sales, versus $0.3 million or 6.4% of sales in the prior year, an increase of approximately 325% in gross profit dollars. Adjusted gross profit⁽¹⁾ was $0.7 million or 4.1% of sales when accounting for the impact of realized currency hedging activities, versus $0.3 million or 5.8% of sales in the prior year.

• Cash operating expenses of $1.2 million or 6.8% of sales versus $0.6 million or 13.4% of sales in the prior year. Operating expenses have stabilized following the sale of three subsidiaries in Q-2 2024, though have increased due to the assumption of operating expenses that were previously borne by the subsidiaries sold, as well as incremental costs to support the growth of our business.

• Loss from operations of $0.3 million versus a loss of $0.4 million in the prior year.

• Net loss for the period of $7.4 million after accounting for interest and accretion costs of $0.2 million and realized and unrealized losses on derivative assets and liabilities totaling $2.5 million. Net loss also includes a number of non-recurring costs including debt restructuring costs of $0.7 million and losses on the settlement of debt of $3.8 million. Net income in the prior year was $2.1 million, driven by a gain from the dissolution of one of the Company’s subsidiaries of $0.4 million and income related to the sale of three operating subsidiaries of $2.3 million, offset by losses related to continuing operations.

Fiscal 2025 Six-Month Results Overview

• Sales of $30.8 million versus $9.0 million in the prior year, an increase of approximately 241%. Sales have grown as new customers have been added, and a number of existing customers have increased their purchases. Six-month sales represent an increase of 49% over total fiscal 2024 sales of $20.7 million, which were previously the largest annual sales for the Company.

• Gross profit of $2.4 million or 7.7% of sales, versus $0.6 million or 6.2% of sales in the prior year, an increase of approximately 325% in gross profit dollars. Adjusted gross profit⁽¹⁾ was $1.8 million or 6.0% of sales when accounting for the impact of realized currency hedging activities, versus $0.5 million or 5.2% of sales in the prior year.

• Cash operating expenses of $2.1 million or 6.7% of sales versus $1.0 million or 11.3% of sales in the prior year. Operating expenses have stabilized following the sale of three subsidiaries in Q-2 2024, though have increased due to the assumption of operating expenses that were previously borne by the subsidiaries sold, as well as incremental costs to support the growth of our business.

• Loss from operations of $0.1 million versus a loss of $0.6 million in the prior year.

• Net loss for the period of $7.6 million after accounting for interest and accretion costs of $0.5 million and realized and unrealized losses on derivative assets and liabilities totaling $2.7 million. Net loss also includes a number of non-recurring costs including debt restructuring costs of $0.7 million and losses on the settlement of debt of $3.8 million. Net income in the prior year was $0.6 million, driven by a gain from the dissolution of one of our subsidiaries of $0.4 million and income related to the sale of three operating subsidiaries of $1.3 million, offset by losses related to continuing operations.

The Company’s filings, including Audited Financial Statements and accompanying Management’s Discussion and Analysis for the year ended December 31, 2024 are available at www.SEDARplus.ca or at the Company’s website at www.organto.com under the Investors tab.

Update on Private Placement

As previously announced on July 31 and August 19, the Company is in the process of closing a non-brokered private placement of 16,000,000 units at a price of $0.50 per unit, with each unit consisting of one common share and one-half common share purchase warrant. The warrants will be exercisable at $0.75 per share for 18 months, with acceleration rights if the share price reaches or exceeds $1.00 for ten consecutive trading days.

Proceeds from the private placement are intended to be used to continue the growth of the Company’s organic and fairtrade fruit and vegetable products, further develop the Company’s technology platform, and support general working capital requirements, and may also be used to repay part of the Company’s short-term debt.

ON BEHALF OF THE BOARD,

Steve Bromley
Co-Chair and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For more information contact:

info@organto.com
John Rathwell, Senior Vice President, Corporate Development
647 629 0018

1. The information presented herein refers to the non-IFRS financial measures of adjusted gross profit and EBITDA. We hedge currencies for certain product categories where either the supply or sales commitments are fixed in foreign currencies. The gains and losses from these hedging activities are combined with gross profit to determine adjusted gross profit. We also refer to EBITDA, which is Earnings before interest, taxes, depreciation and amortization. These two measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS. Non-IFRS financial measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS and are unlikely to be comparable to similar measures presented by other issuers. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective and thus highlight trends in its business that may not otherwise be apparent when relying solely on IFRS measures. The Company believes that securities analysts, investors and other interested parties frequently use non-IFRS financial measures in the evaluation of the Company. The Company’s management also uses non-IFRS financial measures to facilitate operating performance comparisons from period to period and to prepare annual operating budgets and forecasts.

ABOUT ORGANTO FOODS

Organto is an integrated provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-light business model to serve a growing socially responsible and health-conscious consumer around the globe. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto’s belief that the impact of these restructuring efforts is a key driver of its second quarter and six-month results; Organto’s belief that the combination of financing and debt restructuring efforts combined with strong sales and margin growth on a streamlined cost base positions the Company for an exciting future; Organto’s belief that it remains focused on building a world class company focused on growing healthy foods markets with the gaol of building shareholder value; management’s beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto’s business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences taking place in September.

Citi’s 2025 Biopharma Back to School Summit; Boston, MA – September 2-3, 2025
Format: Fireside Chat
Day/Time: Wednesday, September 3 at 9:45 A.M. ET
Webcast: https://kvgo.com/2025-biopharma-back-to-school-conference/protagonist-therapeutics-inc-sep-2025

H.C. Wainwright 27th Annual Global Investment Conference; New York, NY – September 8-10, 2025
Format: Fireside Chat
Day/Time: Tuesday, September 9 at 11:30 A.M. ET
Webcast: https://journey.ct.events/view/2f5c929c-0a3b-473f-a149-bcc3e8c0ed5f

BofA 11^th Annual World Medical Innovation Forum; Boston, MA – September 15-17, 2025
Panel Title: Immunology: Creating the next blockbuster in I&I
Day/Time: Tuesday, September 16

If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.

A replay of the presentations will be available on the Company’s Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and the NDA submission for rusfertide is expected by end of 2025. Icotrokinra (formerly, JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) is licensed to J&J Innovative Medicines (“JNJ”), formerly Janssen Biotech, Inc. Following icotrokinra’s joint discovery by Protagonist and JNJ scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Contact

Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
virginiaamann@ententeinc.com

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

Civics & Debate Club Engages Students Nationwide

PHOENIX, ARIZONA / ACCESS Newswire / August 26, 2025 / The Sandra Day O’Connor Institute is proud to announce that its O’Connor Institute Ambassadors Civics & Debate Club is now open for registration. The high school virtual extracurricular program will focus on America’s founding and the Bill of Rights during the 2025-2026 school year. Meeting via Zoom, students from across the country have the chance to connect through dynamic discussions, participate in small-group breakout debates, and gain valuable insights from policymakers, elected officials, and subject-matter experts. The program was developed for teens to foster civil discourse, expand civic knowledge, and prepare the next generation of leaders to become engaged citizens.

“The Sandra Day O’Connor youth programs embody our mission to promote multigenerational civics education, civic engagement, and civil discourse,” said Philip L. Francis, O’Connor Institute Board of Directors Chair. “We believe young people are eager to lead, and these programs provide the knowledge and skills to do just that.”

In addition to virtual club gatherings throughout the school year, Ambassadors are encouraged to volunteer in their communities. Members in the 12^th grade, set to graduate in spring 2026, are eligible to apply for the $5,000 scholarship from the John Jay Fetzer Memorial Scholarship Fund. The scholarship benefits seniors who demonstrate exceptional academic achievement, leadership, civil debate skills, civics knowledge and community service.

“We are thrilled to provide our nation’s youth an opportunity to learn more about our nation’s form of government,” said Sarah Suggs, President and CEO at the O’Connor Institute. “Our program includes scholarship opportunities, graduation cords and encourage volunteerism.”

For more information and to register for the Ambassador Civics & Debate Club, visit oconnorinstitute.org/ambassadors.

The O’Connor Institute also provides middle school and high school students the opportunity to engage in civics education and civil discourse throughout the year via the Civics Challenge or Camp O’Connor USA.

About the Sandra Day O’Connor Institute

Founded in 2009 by Justice Sandra Day O’Connor following her retirement from the U.S. Supreme Court, the nonpartisan nonprofit continues her distinguished legacy and lifetime work to advance multigenerational civics education, civil discourse and civic engagement. The vision of the Institute is to create a nation where important policy decisions affecting our future are made through a process of critical analysis of facts and informed participation of all citizens. Learn more at OConnorInstitute.org.

Contact Information

Heather Schader
hschader@oconnorinstitute.org
602-730-3300 x8

SOURCE: Sandra Day O’Connor Institute

View the original press release on ACCESS Newswire

Founders Dr. Anatoly and Oksana Ripa bring their patient-focused approach and modern dental care to new communities in North Miami-Dade.

MIAMI, FL / ACCESS Newswire / August 26, 2025 / Smile Creators, a boutique dental practice founded by Dr. Anatoly Ripa and Oksana Ripa, has officially expanded with a new clinic in Sunny Isles Beach, and a third location is coming soon to Aventura. With their flagship office in Bay Harbor Islands already serving a diverse Miami clientele, this expansion marks an exciting new chapter for one of the region’s most innovative dental brands. Dr. Ripa, a graduate of Stony Brook University with over 27 years of experience in the field, is known for his personalized approach to aesthetic and restorative dentistry. Fluent in English, Russian, and Ukrainian, he has built long-term relationships with patients across the Bal Harbour and North Miami areas. Alongside him, Oksana Ripa has helped shape Smile Creators into a recognizable name – developing a patient experience that blends hospitality, precision care, and community connection.

The expansion into Sunny Isles Beach reflects a growing demand for access to personalized, high-quality dental care delivered in a calming and modern environment. The upcoming Aventura office, set to open later this year, will extend the practice’s reach even further into North Miami-Dade.

“Our goal has always been to make patients feel confident, cared for, and in control of their health,” said Dr. Anatoly Ripa. “Every new space we create reflects that vision.”

Technology plays a central role in the Smile Creators’ vision. Each location incorporates modern diagnostic tools and workflow systems that support efficient, individualized treatment. The clinical environment – designed under the creative direction of Oksana Ripa – also avoids the traditional feel of a dental office, opting instead for a relaxed, spa-like atmosphere that helps patients feel at ease.

While many patients visit Smile Creators for cosmetic improvements, the clinic maintains a full-scope dental approach that supports oral health at every stage of life. As the practice continues to grow, its core values remain centered on trust, transparency, and a commitment to long-term results.

The Smile Creators team continues to connect with patients both in-person and online. For more information about their services or to schedule a consultation, visit www.smilecreators.com or follow the clinic’s official Instagram at @smilecreators_miami for updates, behind-the-scenes content, and news on the upcoming Aventura launch.

“We’re proud to grow with the communities we serve,” said Oksana Ripa. “For us, expansion isn’t just about more locations – it’s about deeper relationships with the people who walk through our doors.”

In addition to its clinical services, Smile Creators is known for its bold branding – from its signature yellow vehicle seen across Miami to its stylish clinic interiors and strong social media identity. The brand’s connection to the city remains a central part of its success story.

The Sunny Isles Beach location is now open to patients. The Aventura office is currently in development, with a grand opening expected later this year.

Contact:

VUGA Media Group
Miami, FL
Alice Bay
contact@vugamediagroup.com

SOURCE: VUGA Media Group

View the original press release on ACCESS Newswire